Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: iana5252 on November 10, 2021, 03:18:34 pm

Title: Six Weeks May Not Be Enough for Early Hepatitis C Treatment
Post by: iana5252 on November 10, 2021, 03:18:34 pm
People with acute or recently acquired hepatitis C who received a six-week course of Epclusa (sofosbuvir/velpatasivir) were more likely to relapse and less likely to be cured than those treated for 12 weeks, according to results from the REACT trial.

The advent of direct-acting antivirals has made hepatitis C treatment shorter, better tolerated and much more effective than previous interferon-based therapy. The typical course of treatment for chronic hepatitis C virus (HCV) infection now ranges from eight weeks of Mavyret (glecaprevir/pibrentasvir) for previously untreated people to 12 weeks of Mavyret, Epclusa or Harvoni (sofosbuvir/ledipasvir) for most treatment-experienced patients.

Read more:
https://www.hepmag.com/article/six-weeks-may-enough-early-hepatitis-c-treatment